- Home
- SDGR vs WGS Comparison
SDGR vs WGS Comparison
Compare SDGR & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDGR
- WGS
- Stock Information
- Founded
- SDGR 1990
- WGS 2017
- Country
- SDGR United States
- WGS United States
- Employees
- SDGR N/A
- WGS N/A
- Industry
- SDGR Biotechnology: Pharmaceutical Preparations
- WGS Retail: Computer Software & Peripheral Equipment
- Sector
- SDGR Health Care
- WGS Technology
- Exchange
- SDGR Nasdaq
- WGS Nasdaq
- Market Cap
- SDGR 1.8B
- WGS 2.0B
- IPO Year
- SDGR 2020
- WGS N/A
- Fundamental
- Price
- SDGR $22.64
- WGS $95.83
- Analyst Decision
- SDGR Buy
- WGS Strong Buy
- Analyst Count
- SDGR 9
- WGS 5
- Target Price
- SDGR $32.11
- WGS $82.60
- AVG Volume (30 Days)
- SDGR 1.0M
- WGS 1.4M
- Earning Date
- SDGR 02-26-2025
- WGS 02-18-2025
- Dividend Yield
- SDGR N/A
- WGS N/A
- EPS Growth
- SDGR N/A
- WGS N/A
- EPS
- SDGR N/A
- WGS N/A
- Revenue
- SDGR $193,348,000.00
- WGS $305,450,000.00
- Revenue This Year
- SDGR N/A
- WGS $44.70
- Revenue Next Year
- SDGR $31.43
- WGS $16.73
- P/E Ratio
- SDGR N/A
- WGS N/A
- Revenue Growth
- SDGR N/A
- WGS 50.79
- 52 Week Low
- SDGR $16.67
- WGS $7.16
- 52 Week High
- SDGR $33.63
- WGS $115.60
- Technical
- Relative Strength Index (RSI)
- SDGR 43.67
- WGS 59.30
- Support Level
- SDGR $23.14
- WGS $65.10
- Resistance Level
- SDGR $28.47
- WGS $115.60
- Average True Range (ATR)
- SDGR 1.60
- WGS 9.03
- MACD
- SDGR -0.34
- WGS 3.96
- Stochastic Oscillator
- SDGR 9.19
- WGS 65.30
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.
About WGS GeneDx Holdings Corp.
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. GeneDx is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.